This study is a prospective, single center, open label, single arm clinical study. Select resectable locally advanced (cT3-4aN0M0, cT1-3N1-2M0, cII/III stage) esophageal cancer with pathological diagnosis of squamous cell carcinoma for inclusion, receive pembrolizumab combined with platinum containing dual drug (albumin paclitaxel+carboplatin) treatment for 2 courses, and undergo surgery. After surgery, continue pembrolizumab immunotherapy. Using pCR as the main endpoint of the study
Baseline stage resectable cII/III esophageal squamous cell carcinoma (8th UICC TNM stage);
Failure to receive anti-tumor treatment for esophageal squamous cell carcinoma;
Age range from 18 to 75 years old;
There are no surgical contraindications in the preoperative evaluation of various organ functions;
Individuals who have received previous treatment for esophageal cancer (surgery, radiotherapy, chemotherapy, immunotherapy, targeted therapy, etc.);
Not suitable for surgery or with surgical contraindications;
Have a history of other anti PD-L1/PD-1 treatments;
Individuals with immunodeficiency or long-term systemic steroid therapy, or those who have received any immunosuppressive therapy within 7 days prior to receiving the study drug;